Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

and a low rate of stent thrombosis from zero to three years, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)*. The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

Event rates based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

"The data from the SPIRIT family of trials continue to prove that XIENCE V is an excellent option for patients. Physicians have embraced this technology, as demonstrated by the market-leading position of XIENCE V around the world," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Our next-generation drug eluting stent in development, XIENCE PRIME, builds upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials, while the new stent design and its delivery system build upon the excellent performance of the VISION cobalt chromium platform, improving deliverability and helping physicians treat difficult lesions."

XIENCE V is the market-leading drug eluting stent platform, with 50 percent share in the United States, and market-leading share around the world.

Abbott's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System utilizes the same drug and polymer as Abbott's market-leading XIENCE V stent and builds upon the proven design of the MULTI-LINK(R) family of stents. XIENCE PRIME features a new stent design and delivery system that are designed to make it more flexible for improved deliverability. Abbott plans to make XIENCE PRIME available in an expanded size matrix with lengths up to 38 mm. The company expects to launch XIENCE PRIME in Europe later this year.

About the SPIRIT II Trial

SPIRIT II is a prospective
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
(Date:9/16/2014)... 2014 On September 25 to 26, 2014, ... medical design and manufacturing - MEDTEC China  - will ... Exhibition & Convention Center, bringing together close to 300 ... showcase their latest medical-grade raw materials, parts and processing ... remaining for free visitor pre-registration to be completed. To ...
(Date:9/16/2014)... 16, 2014 CorMedix Inc. ("CorMedix") (NYSE ... and commercializing therapeutic products for the prevention and ... the amendment and restatement of its outstanding Series ... related warrants, as well as the warrants issued ... financing, to remove anti-dilution, price reset and certain ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... 2014 The second federal bellwether trial ... Johnson subsidiary Ethicon concluded with the jury in the ... awarding her $3.27 million in damages, according to a ... “jurors found Ethicon liable for selling faulty devices and ... were at risk from side effects that include pain, ...
(Date:9/16/2014)... 16, 2014 Advanced Fertility Center of ... by Houstonia Magazine as one of the Top Doctors ... Magazine - a metropolitan magazine serving the Houston area. ... recognize them for their outstanding services. This accomplishment will ... of Houstonia Magazine — a special publication listing all ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is ... and Gratafy for a fun evening of tech networking. ... cemented. With the growth of companies in these sectors, there’s also ... work in tech and at startups to connect with each other. ... to host events for their peers to meet and mingle in ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... This year’s theme is centered around entrepreneurism ... Mills, Pennsylvania, September 15, 2014- Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Steven Reinberg HealthDay Reporter , MONDAY, March ... second of three reactors at earthquake-ravaged Japan,s Fukushima Dai-ichi ... the facility were safe, according to news reports. ... with seawater after Friday,s devastating earthquake and tsunami knocked ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... International Liver CongressTM is an opportunity for over ... to hear the latest research, perspectives and treatments ... field. It features a high-calibre and multi-disciplinary scientific ... the most essential topics. EASL will hold ...
... taken by certain women as a preventive measure against breast ... conclusion of a new study published early online in ... The study,s results suggest that the benefits of tamoxifen to ... post-menopausal women under age 55 years who have an increased ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
Cached Medicine News:Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:International Liver Congress 2011 2Health News:Taking tamoxifen to prevent breast cancer can save lives and money 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3
... Digisonics is a web-based application to securely ... cardiovascular modalities. Users can login from ... password to review stored patient studies. ... patient information, images, and reports Quickly locates ...
... stands for Stainless Steel Kleener. SSK-80 is ... and stain remover for ultra-sonic cleaners. , ... of your instruments by removing and inhibiting ... pivot points, box joints and moving instrument ...
... Foam is the ready-to-use, pre-cleaning enzymatic foam ... ,Hemaway Enzymatic Foam sprays on ... It's perfect for use in the O.R. ... Getting a head start with Hemaway Enzymatic ...
... Cytospin has been synonymous with ... More than 15,000 laboratories worldwide ... It provides economical thin-layer preparations ... hypocellular fluids such as spinal ...
Medicine Products: